Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19103337 | 0.87 | GSK3B (0.43) | GSK3BMKNK2CA12CA1CA2 | |
| SCHEMBL17542604 | 0.81 | MKNK2 (0.53) | POLBGSK3BALDH1A1MAPTMKNK2 | |
| SCHEMBL22510213 | 0.81 | GAA (0.50) | GAAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL17384835 | 0.80 | GAA (0.49) | GAAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL19254498 | 0.79 | GSK3B (0.48) | GSK3BMKNK2MKNK1EGFR | |
| SCHEMBL19532488 | 0.79 | MKNK2 (0.54) | GSK3BMKNK2CA12CA1CA2 | |
| SCHEMBL30883818 | 0.77 | GSK3B (0.49) | POLBGSK3BMEN1KMT2AMKNK2 | |
| SCHEMBL17822343 | 0.77 | GSK3B (0.49) | POLBGSK3BMEN1KMT2AMKNK2 | |
| SCHEMBL21596385 | 0.77 | POLB (0.61) | GAAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL22585743 | 0.77 | EGFR (0.49) | GSK3BMKNK2MKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2015195228-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | GAA 535/4885POLB 1649/4885GSK3B 326/4885 |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | GAA 535/4885POLB 1649/4885GSK3B 326/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | GAA 535/4885POLB 1649/4885GSK3B 326/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | GAA 535/4885POLB 1649/4885GSK3B 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.